Qiuhui Sun, Min Liang, Tingting You
Patients with AML have a poor prognosis due to recurrence and high-risk genetic factors. lncRNA OIP5-AS1 exhibits differential expression among AML patients with varying genetic risks. The aim of this study is to examine the clinical value and regulation mechanisms of OIP5-AS1 in AML. RT-qPCR was used to evaluate the OIP5-AS1, miR-15a-5p, and FOXO1 levels in patients with AML and cells, as well as the mRNA levels of Bcl-2, Bax, and Caspase-3 in AML cell. The CCK-8 test was employed to measure cell proliferation. Apoptosis rates were detected by flow cytometry. DLR experiments validated the interaction between OIP5-AS1, miR-15a-5p, and FOXO1. Compared with the controls, AML patients exhibited notably elevated levels of OIP5-AS1 and FOXO1, along with markedly reduced miR-15a-5p expression. Furthermore, OIP5-AS1 levels effectively differentiate patients with AML from controls. Patients in the high OIP5-AS1 level group exhibited lower 5-year survival rates. Knockdown of OIP5-AS1 elevated miR-15a-5p levels, reduced cell proliferation capacity, and notably increased apoptosis. Furthermore, FOXO1, as a target gene of miR-15a-5p, showed a positive correlation with OIP5-AS1 level and a negative correlation with miR-15a-5p level. OIP5-AS1 exhibits significant diagnostic and prognostic value in AML, showing promise as a novel clinical biomarker. Knockdown of OIP5-AS1 leads to upregulation of miR-15a-5p level, thereby influencing proliferation and apoptosis processes in AML cells. This mechanism may provide a new therapeutic target for improving the prognosis of AML patients.